These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38801467)

  • 1. Comment on 'Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis'.
    Zhao J; Xu Q
    Int J Surg; 2024 Sep; 110(9):5895-5896. PubMed ID: 38801467
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H
    Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
    Powles T; Chang YH; Yamamoto Y; Munoz J; Reyes-Cosmelli F; Peer A; Cohen G; Yu EY; Lorch A; Bavle A; Homet Moreno B; Markensohn J; Edmondson M; Chen C; Cristescu R; Peña C; Lunceford J; Gunduz S
    Nat Med; 2024 Sep; 30(9):2508-2516. PubMed ID: 38823511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Fujiwara Y; Karol AB; Joshi H; Reford E; Izadmehr S; Doroshow DB; Galsky MD
    Crit Rev Oncol Hematol; 2024 May; 197():104352. PubMed ID: 38614269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
    J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
    Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer.
    Kouba E; Cheng L
    Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200
    [No Abstract]   [Full Text] [Related]  

  • 9. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
    Shohdy KS; Villamar DM; Cao Y; Trieu J; Price KS; Nagy R; Tagawa ST; Molina AM; Sternberg CN; Nanus DM; Mosquera JM; Elemento O; Sonpavde GP; Grivas P; Vogelzang NJ; Faltas BM
    Br J Cancer; 2022 Feb; 126(3):430-439. PubMed ID: 35046520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
    Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.
    Rink M; Schwarzenbach H; Riethdorf S; Soave A
    World J Urol; 2019 Sep; 37(9):1785-1799. PubMed ID: 30367205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ca 125 as a marker of tumor activity in advanced urothelial malignancy.
    Izes JK; Dyer MW; Callum MG; Bankes P; Libertino JA; Caffrey JA
    J Urol; 2001 Jun; 165(6 Pt 1):1908-13. PubMed ID: 11371879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of Chinese patients with urothelial carcinoma.
    Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
    BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating biomarkers to guide systemic therapy for urothelial carcinoma.
    Abbosh PH; Rosenberg JE; Plimack ER
    Urol Oncol; 2016 Nov; 34(11):502-509. PubMed ID: 27751785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A commentary on 'Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis'.
    Tu X; Zhang T
    Int J Surg; 2024 Sep; 110(9):5885-5886. PubMed ID: 39275775
    [No Abstract]   [Full Text] [Related]  

  • 16. Using Circulating Tumor DNA To Guide Adjuvant Therapy in Bladder Cancer: IMvigor010 and IMvigor011.
    Grunewald CM; Niegisch G; Albers P
    Eur Urol Focus; 2022 May; 8(3):646-647. PubMed ID: 35450799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 Oct; 86(4):301-311. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Circulating tumor DNA (ctDNA) in urothelial carcinoma-the long-desired biomarker?].
    Grunewald CM; Niegisch G
    Urologe A; 2021 Nov; 60(11):1466-1467. PubMed ID: 34618167
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum D-asparagine concentration adjusted for eGFR could serve as a novel screening tool for urothelial carcinoma.
    Yamamoto A; Kawashima A; Sakai S; Mita M; Sassi N; Inoguchi S; Horibe Y; Yoshimura A; Tani M; Yutong L; Okuda Y; Oka T; Uemura T; Yamamichi G; Ishizuya Y; Hayashi T; Yamamoto Y; Kato T; Hatano K; Kakuta Y; Imamura R; Takahara S; Kimura T; Nonomura N
    Biochem Biophys Res Commun; 2024 Nov; 733():150701. PubMed ID: 39326256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.
    Grivas P; Lalani AA; Pond GR; Nagy RJ; Faltas B; Agarwal N; Gupta SV; Drakaki A; Vaishampayan UN; Wang J; Barata PC; Gopalakrishnan D; Naik G; McGregor BA; Kiedrowski LA; Lanman RB; Sonpavde GP
    Eur Urol Oncol; 2020 Oct; 3(5):695-699. PubMed ID: 31412004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.